Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Pharma Labor Platform Calls for Inflation-Responsive Drug Pricing Reforms, Opposes CEA Expansion
July 3, 2025
- Japan’s Contract Rep Ratio Hits Record as Biotechs, Foreign Firms Drive Demand
July 1, 2025
- FPMAJ Chair Questions Sakigake as Incentive for Prioritizing Japan R&D
June 24, 2025
- JGA Targets FY2027 for Resolving Drug Shortages, Two Years Ahead of Forecast
June 20, 2025
- Generic Use Rate at 89.0% in January: Payer
June 18, 2025
- JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
- 84% of Pharmacies See More Generic Dispensing after Rollout of New LLP Rule: FPMAJ
June 17, 2025
- FPMAJ Calls for Relaxation of Support Rules for Low-Priced Drugs
June 17, 2025
- FPMAJ Calls for Expanded Range of Selection for Comparator Drugs
June 16, 2025
- PMP Drugs Should Be Excluded from Price Revisions: FPMAJ Committee Chief
June 16, 2025
- JPMA Ready to Engage with Government on CEA Debates: Statement
June 16, 2025
- Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
- Hata Comes Back to Helm FIRM after 2 Years
June 10, 2025
- Pharma FTC Revises Food and Drink Rules for Doctors for 1st Time in 10-Plus Years
June 5, 2025
- New FPMAJ Chair Pushes Category-Based Drug Pricing to Ensure Innovation, Stable Supply
June 5, 2025
- New JPMA Chief Calls for Clear-Cut Evaluation of Innovation in FY2026 Reform
June 3, 2025
- Revamp Drug Price System to Make Room for Wage Hikes: Labor Union
May 29, 2025
- JPMA Revises Definition of Promotion in Code of Practice
May 27, 2025
- FPMAJ Sets Out on New Lobbying Push with Astellas’ Yasukawa as New Chief
May 23, 2025
- Takeda’s Miyabashira Elected as New JPMA President
May 23, 2025
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…